In summary, if GnRH agonists are used for ovarian stimulation, the expected incidence of moderate/severe OHSS is 6.43% and 10.61% in the regular population and in patients with PCOS, respectively. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.